{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:19:25Z","timestamp":1791263965509,"version":"4.1.0"},"reference-count":24,"publisher":"S. Karger AG","issue":"4","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2006]]},"abstract":"<i>Objective:<\/i> It was the aim of this study to evaluate the safety of the optimized cryptic peptide TERT<sub>572Y<\/sub> in pretreated patients with advanced cancer. <i>Methods:<\/i> Nineteen patients with progressive and chemotherapy-refractory tumors received escalated doses (2\u20136 mg) of 2 subcutaneous injections of the optimized TERT<sub>572Y<\/sub> peptide followed by 4 subcutaneous injections of the native TERT<sub>572<\/sub> peptide every 3 weeks. Both TERT peptides were coinjected with adjuvant Montanide ISA51. Toxicity was evaluated every 3 weeks and peptide-specific CD8+ cells were detected by flow cytometry using TERT<sub>572Y<\/sub> tetramers. <i>Results:<\/i> Fourteen out of 19 patients completed the vaccination program. No grade III\/IV toxicity was observed. Grade I anemia was observed in 4 patients and local skin reaction at the injection site in 11 patients. Other nonhematologic toxicities were mild, and no late toxicity was observed after a median postvaccination follow-up period of 10.7 months. There was no dose-limiting toxicity. Peripheral blood TERT<sub>572Y<\/sub>-specific CD8+ lymphocytes were detected in 13 out of 14 evaluable patients after 2 injections with the optimized TERT<sub>572Y<\/sub> peptide. There was no complete or partial response, but 4 patients (21%) with persistent TERT<sub>572Y<\/sub>-specific CD8+ experienced stable disease for a median of 10.5 months. <i>Conclusion:<\/i> TERT<sub>572Y<\/sub> peptide vaccine is well tolerated and effective in eliciting specific TERT<sub>572Y<\/sub> CD8+ lymphocytes in pretreated cancer patients, demonstrating that cryptic peptides could be used in cancer immunotherapy.<\/jats:p>","DOI":"10.1159\/000096252","type":"journal-article","created":{"date-parts":[[2006,10,18]],"date-time":"2006-10-18T07:02:17Z","timestamp":1161154937000},"page":"306-314","source":"Crossref","is-referenced-by-count":47,"title":["A Phase I Study of the Optimized Cryptic Peptide TERT<sub>572Y<\/sub> in Patients with Advanced Malignancies"],"prefix":"10.1159","volume":"70","author":[{"given":"D.","family":"Mavroudis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Bolonakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Cornet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Myllaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kanellou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kotsakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Galanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Nikoloudi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Spyropoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Menez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Miconnet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Niniraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cordopatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Kosmatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Georgoulias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2006,10,31]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2F0167-5699%2894%2990172-4"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1158%2F1078-0432.CCR-04-0325"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1158%2F1078-0432.CCR-0620-3"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.89.1.416"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1172%2FJCI200419418"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1084%2Fjem.185.5.833"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1084%2Fjem.191.7.1221"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097%2F00002371-200105000-00007"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002%2F1521-4141%282000012%2930%3A12%3C3411%3A%3AAID-IMMU3411%3E3.0.CO%3B2-R"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1126%2Fscience.7605428"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.182418399"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109%2F07357909009017560"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002%2F1097-0142%2819810101%2947%3A1%3C207%3A%3AAID-CNCR2820470134%3E3.0.CO%3B2-6"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1158%2F1078-0432.CCR-04-0325"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016%2FS1074-7613%2800%2980066-7"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.070560797"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002%2F1521-4141%28200109%2931%3A9%3C2642%3A%3AAID-IMMU2642%3E3.0.CO%3B2-6"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2003.10.005"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097%2F00002371-199909000-00007"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2002.06.171"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2004.09.005"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1002%2F%28SICI%291097-0215%2819970611%2971%3A6%3C932%3A%3AAID-IJC3%3E3.0.CO%3B2-Z"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1073%2Fpnas.96.9.5147"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1111%2Fj.1600-065X.1997.tb00982.x"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/96252","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/96252","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:51:05Z","timestamp":1745463065000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000096252"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":24,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2006,10,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000096252","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006]]}}}